Galenika a.d.

Galenika a.d.
Native name
 Галеника а.д.
Joint-stock company
Traded as BELEX: FITO
Industry Pharmaceuticals
Founded 30 April 1991 (1991-04-30) (Current form)
First founded in 1945
Headquarters Zemun, Belgrade, Serbia
Key people
 Nedeljko Pantić (general director)
Products Generic drugs, over-the-counter drugs, medical devices
Revenue Decrease €42.96 million (2017)[1]
Increase €61.96 million (2017)[1]
Total assets Decrease €147.48 million (2017)[2]
Total equity Increase €90.96 million (2017)[2]
Owner Aelius (93.73%)
Others
Number of employees
 1,550 (2017)
Subsidiaries Galing d.o.o.
Galenika Banja Luka d.o.o.
Galenika Crna Gora d.o.o.
Galenika Klirit d.o.o.
Website www.galenika.rs
Footnotes / references
Business ID: 07725531
Tax ID: 100001046 [3]

Galenika a.d. (Serbian Cyrillic: Галеника а.д.) is a Serbian pharmaceutical company with headquarters in Zemun, Belgrade.

History

Founded in 1945, Galenika was a major pharmaceutical drug-maker in the Balkans with exports to Europe, Africa and Asia.

As of 2006, Galenika remained a leader in research and development as the only pharmaceutical company in Serbia with an institute registered with the Ministry of Science and Environmental Protection.[4]

By the 2010-s, most of the Serbian formerly domestically controlled pharmaceutical market, has shifted in foreign hands.[5] Galenika, once a giant which controlled over half of Serbian market share and a large portion of former Yugoslavia, has deteriorated greatly since the start of the Yugoslav wars and subsequently during the 2000-s.

Since 2013, the Government of Serbia has begun seeking a partner for Galenika through the privatization process.[6] However, over the years several privatization auction processes have failed.

In August 2017, the Government of Serbia converted company's debts to state into shares in ownership structure, worth 14.696 billion dinars (122.81 million euros).[7] In November 2017, Luxembourg's investment fund Aelius (related to the Brazilian largest pharmaceutical company EMS) purchased 93.73% of the company's shares from the Government of Serbia for a total of 16 million euros.[8]

Logos

From 1945, Galenika has changed four different logos. The first logo of company was used from 1945 to 1992, the second logo from 1992 to 1998 (which has been marked as ICN Galenika), the third logo was used from 1998 to 2002, and the fourth and incumbent logo has been in use since 2002.

Market and financial data

According to 2016 annual financial report submitted to Serbian Business Registers Agency (APR), the company has 1,595 employees and it posted an annual loss of 10.45 million euros.[1] As of 30 January 2018, Galenika has a market capitalization of €63.17 million.[9]

References

  1. 1 2 3 "КОНСОЛИДОВАНИ БИЛАНС УСПЕХА (2017) - Галеника". apr.gov.rs (in Serbian). Retrieved 9 October 2018.
  2. 1 2 "КОНСОЛИДОВАНИ БИЛАНС СТАЊА (2017) - Галеника". apr.gov.rs (in Serbian). Retrieved 9 October 2018.
  3. ↑ "Основни подаци о привредном друштву". apr.gov.rs (in Serbian). Serbian Business Registers Agency. Retrieved 28 February 2018.
  4. ↑ Doing Business with Serbia By Marat Terterov, Consultant Editor, Marat Terterov, Inc NetLibrary; Published by GMB Publishing Ltd, 2006; ISBN 1-905050-68-2, ISBN 978-1-905050-68-0.
  5. ↑ Telesković, Anica (23 September 2017). "Stranci drže više od dve trećine tržišta lekova". politika.rs (in Serbian). Retrieved 12 November 2017.
  6. ↑ "Serbia to Start Sale of Galenika Drugmaker in Early 2013". Bloomberg. 13 December 2012. Retrieved 9 April 2013.
  7. ↑ "Država povećala vlasnički udeo u Galenici". blic.rs (in Serbian). Tanjug. 14 August 2017. Retrieved 9 October 2018.
  8. ↑ "Potpisano: Galenika prodata Eliusu". b92.net (in Serbian). 2 November 2017. Retrieved 12 November 2017.
  9. ↑ "FITO - Galenika Fitofarmacija a.d. , Zemun - 30.01.2018". belex.rs. Retrieved 30 January 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.